During the last session, Can-Fite Biopharma Ltd ADR (AMEX:CANF)’s traded shares were 0.35 million, with the beta value of the company hitting 1.17. At the end of the trading day, the stock’s price was $1.20, reflecting an intraday loss of -2.44% or -$0.03. The 52-week high for the CANF share is $4.69, that puts it down -290.83 from that peak though still a striking 1.67% gain since the share price plummeted to a 52-week low of $1.18. The company’s market capitalization is $12.54M, and the average intraday trading volume over the past 10 days was 0.7 million shares, and the average trade volume was 280.91K shares over the past three months.
Can-Fite Biopharma Ltd ADR (CANF) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CANF has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Can-Fite Biopharma Ltd ADR (AMEX:CANF) trade information
Can-Fite Biopharma Ltd ADR (CANF) registered a -2.44% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.44% in intraday trading to $1.20, hitting a weekly high. The stock’s 5-day price performance is -14.16%, and it has moved by -26.32% in 30 days. Based on these gigs, the overall price performance for the year is -42.31%. The short interest in Can-Fite Biopharma Ltd ADR (AMEX:CANF) is 0.38 million shares and it means that shorts have 1.14 day(s) to cover.
The consensus price target of analysts on Wall Street is $4.5, which implies an increase of 73.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.5 and $4.5 respectively. As a result, CANF is trading at a discount of -275.0% off the target high and -275.0% off the low.
Can-Fite Biopharma Ltd ADR (CANF) estimates and forecasts
In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year. An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 52.35%. While earnings are projected to return 15.09% in 2025.
CANF Dividends
Can-Fite Biopharma Ltd ADR is due to release its next quarterly earnings on 2024-Mar-27. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
